TY - JOUR AU - Sepulveda, A. R. AU - Hamilton, S. R. AU - Allegra, C. J. PY - 2017 DA - 2017// TI - Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.9807 DO - 10.1200/JCO.2016.71.9807 ID - Sepulveda2017 ER - TY - JOUR AU - Rubenstein, J. H. AU - Enns, R. AU - Heidelbaugh, J. PY - 2015 DA - 2015// TI - American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome JO - Gastroenterology VL - 149 UR - https://doi.org/10.1053/j.gastro.2015.07.036 DO - 10.1053/j.gastro.2015.07.036 ID - Rubenstein2015 ER - TY - JOUR AU - Ribic, C. M. AU - Sargent, D. J. AU - Moore, M. J. PY - 2003 DA - 2003// TI - Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa022289 DO - 10.1056/NEJMoa022289 ID - Ribic2003 ER - TY - JOUR AU - Jover, R. AU - Zapater, P. AU - Castells, A. PY - 2009 DA - 2009// TI - The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.07.016 DO - 10.1016/j.ejca.2008.07.016 ID - Jover2009 ER - TY - JOUR AU - Overman, M. J. AU - McDermott, R. AU - Leach, J. L. PY - 2017 DA - 2017// TI - Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30422-9 DO - 10.1016/S1470-2045(17)30422-9 ID - Overman2017 ER - TY - JOUR AU - Overman, M. J. AU - Lonardi, S. AU - Wong, K. Y. M. PY - 2018 DA - 2018// TI - Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.76.9901 DO - 10.1200/JCO.2017.76.9901 ID - Overman2018 ER - TY - JOUR AU - Longo, D. L. PY - 2012 DA - 2012// TI - Tumor heterogeneity and personalized medicine JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMe1200656 DO - 10.1056/NEJMe1200656 ID - Longo2012 ER - TY - JOUR AU - Vogelstein, B. AU - Papadopoulos, N. AU - Velculescu, V. E. PY - 2013 DA - 2013// TI - Cancer genome landscapes JO - Science VL - 339 UR - https://doi.org/10.1126/science.1235122 DO - 10.1126/science.1235122 ID - Vogelstein2013 ER - TY - JOUR AU - Suzuki, Y. AU - Ng, S. B. AU - Chua, C. PY - 2017 DA - 2017// TI - Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer JO - Mol Oncol VL - 11 UR - https://doi.org/10.1002/1878-0261.12012 DO - 10.1002/1878-0261.12012 ID - Suzuki2017 ER - TY - JOUR AU - Kim, S. T. AU - Cristescu, R. AU - Bass, A. J. PY - 2018 DA - 2018// TI - Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0101-z DO - 10.1038/s41591-018-0101-z ID - Kim2018 ER - TY - JOUR AU - Yim, K. L. PY - 2012 DA - 2012// TI - Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome JO - Med Oncol VL - 29 UR - https://doi.org/10.1007/s12032-011-0050-6 DO - 10.1007/s12032-011-0050-6 ID - Yim2012 ER - TY - JOUR AU - Chapusot, C. AU - Martin, L. AU - Bouvier, A. M. PY - 2002 DA - 2002// TI - Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas JO - Br J Cancer VL - 87 UR - https://doi.org/10.1038/sj.bjc.6600474 DO - 10.1038/sj.bjc.6600474 ID - Chapusot2002 ER - TY - JOUR AU - Joost, P. AU - Veurink, N. AU - Holck, S. PY - 2014 DA - 2014// TI - Heterogenous mismatch-repair status in colorectal cancer JO - Diagn Pathol VL - 9 UR - https://doi.org/10.1186/1746-1596-9-126 DO - 10.1186/1746-1596-9-126 ID - Joost2014 ER - TY - JOUR AU - Tachon, G. AU - Frouin, E. AU - Karayan-Tapon, L. PY - 2018 DA - 2018// TI - Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice JO - Eur J Cancer VL - 95 UR - https://doi.org/10.1016/j.ejca.2018.01.087 DO - 10.1016/j.ejca.2018.01.087 ID - Tachon2018 ER - TY - JOUR AU - Remo, A. AU - Fassan, M. AU - Lanza, G. PY - 2016 DA - 2016// TI - Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal JO - Pathologica VL - 108 ID - Remo2016 ER - TY - JOUR AU - Guinney, J. AU - Dienstmann, R. AU - Wang, X. PY - 2015 DA - 2015// TI - The consensus molecular subtypes of colorectal cancer JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3967 DO - 10.1038/nm.3967 ID - Guinney2015 ER - TY - JOUR AU - Watson, N. AU - Grieu, F. AU - Morris, M. PY - 2007 DA - 2007// TI - Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer JO - J Mol Diagn VL - 9 UR - https://doi.org/10.2353/jmoldx.2007.060162 DO - 10.2353/jmoldx.2007.060162 ID - Watson2007 ER - TY - JOUR AU - Mestier, L. AU - Manceau, G. AU - Neuzillet, C. PY - 2014 DA - 2014// TI - Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review JO - World J Gastrointest Oncol VL - 6 UR - https://doi.org/10.4251/wjgo.v6.i6.156 DO - 10.4251/wjgo.v6.i6.156 ID - Mestier2014 ER - TY - JOUR AU - Cohen, R. AU - Hain, E. AU - Buhard, O. PY - 2019 DA - 2019// TI - Association of Primary Resistance to immune checkpoint inhibitors in metastatic colorectal Cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status JO - JAMA Oncol VL - 5 UR - https://doi.org/10.1001/jamaoncol.2018.4942 DO - 10.1001/jamaoncol.2018.4942 ID - Cohen2019 ER - TY - JOUR AU - Saridaki, Z. AU - Saegart, X. AU - Vriendt, V. PY - 2015 DA - 2015// TI - KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? JO - Br J Cancer VL - 113 UR - https://doi.org/10.1038/bjc.2015.307 DO - 10.1038/bjc.2015.307 ID - Saridaki2015 ER - TY - JOUR AU - Overman, M. J. AU - Lonardi, S. AU - Leone, F. PY - 2017 DA - 2017// TI - Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142 JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.4_suppl.519 DO - 10.1200/JCO.2017.35.4_suppl.519 ID - Overman2017 ER - TY - JOUR AU - Goodman, A. M. AU - Kato, S. AU - Bazhenova, L. PY - 2017 DA - 2017// TI - Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-17-0386 DO - 10.1158/1535-7163.MCT-17-0386 ID - Goodman2017 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Vareki, S. M. PY - 2018 DA - 2018// TI - High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0479-7 DO - 10.1186/s40425-018-0479-7 ID - Vareki2018 ER - TY - JOUR AU - Schrock, A. B. AU - Ouyang, C. AU - Sandhu, J. AU - Sokol, E. AU - Jin, D. AU - Ross, J. S. AU - Miller, V. A. AU - Lim, D. AU - Amanam, I. AU - Chao, J. AU - Catenacci, D. AU - Cho, M. AU - Braiteh, F. AU - Klempner, S. J. AU - Ali, S. M. AU - Fakih, M. PY - 2019 DA - 2019// TI - Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer JO - Annals of Oncology VL - 30 UR - https://doi.org/10.1093/annonc/mdz134 DO - 10.1093/annonc/mdz134 ID - Schrock2019 ER - TY - STD TI - Williams DS, Mouradov D, Jorissen RN, et al. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2018. ID - ref26 ER - TY - JOUR AU - Galon, J. AU - Costes, A. AU - Sanchez-Cabo, F. PY - 2006 DA - 2006// TI - Type, density, and location of immune cells within human colorectal tumors predict clinical outcome JO - Science VL - 313 UR - https://doi.org/10.1126/science.1129139 DO - 10.1126/science.1129139 ID - Galon2006 ER - TY - JOUR AU - Grothey, A. AU - Cutsem, E. AU - Sobrero, A. PY - 2013 DA - 2013// TI - Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61900-X DO - 10.1016/S0140-6736(12)61900-X ID - Grothey2013 ER - TY - STD TI - Teufel M, Schwenke S, Seidel H, et al. Molecular subtype and outcomes in regorafenib-treated patients with metastatic colorectal cancer enrolled in CORRECT trial: ASCO; 2015;33(15_suppl)3558. ID - ref29 ER -